Fluorine-18-THK 5351

Drug Profile

Fluorine-18-THK 5351

Alternative Names: [18F]THK-5351; F-18 THK-5351; FluoroTau; GE-216

Latest Information Update: 25 Jan 2017

Price : $50

At a glance

  • Originator Tohoku University
  • Developer GE Healthcare; Tohoku University
  • Class Antidementias; Imaging agents; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Clinical Phase Unknown Aphasia; Lewy body disease; Mild cognitive impairment; Progressive supranuclear palsy

Most Recent Events

  • 17 Jan 2017 Columbia University and National Institute on Aging plan the phase II TAUPET trial for Diabetes mellitus and Alzheimer's disease (Diagnosis) in USA (IV) (NCT03024944)
  • 24 Oct 2016 Clinical trials in Progressive supranuclear palsy (Diagnosis) in Japan (IV) (UMIN000024541)
  • 24 Oct 2016 Clinical trials in Alzheimer's disease (Diagnosis) in Japan (IV) (UMIN000024541)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top